AstraZeneca PLC (AZN)vsNasus Pharma Ltd. (NSRX)
AZN
AstraZeneca PLC
$185.78
+0.93%
HEALTHCARE · Cap: $284.63B
NSRX
Nasus Pharma Ltd.
$2.76
+10.84%
HEALTHCARE · Cap: $29.28M
Smart Verdict
WallStSmart Research — data-driven comparison
AZN leads profitability with a 17.4% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 66/100 (B-).
AZN
Strong Buy66
out of 100
Grade: B-
NSRX
Avoid17
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+32.8%
Fair Value
$306.07
Current Price
$185.78
$120.29 discount
Intrinsic value data unavailable for NSRX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
No standout strengths identified
Areas to Watch
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : NSRX
NSRX has a balanced fundamental profile.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Revenue Growth, Altman Z-Score.
Bear Case : NSRX
The primary concerns for NSRX are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
AZN is growing revenue faster at 4.1% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AZN scores higher overall (66/100 vs 17/100), backed by strong 17.4% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Nasus Pharma Ltd.
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Nasus Pharma Ltd. is a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. The company is headquartered in Tel Aviv-Yafo, Israel.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?